ARDELYX INC

Ardelyx’s 2026 guidance cut sparks 18% stock plunge – Q2 revenue rises yet investor confidence wavers. Explore how the company plans to regain growth.

Ardelyx’s Q2 2026 results reveal a 31% revenue surge, solid cash reserves, and a bullish outlook for its hyperphosphatemia drugs IBSRELA and XPHOZAH, positioning the company for growth amid a rapidly expanding CKD market.

Ardelyx, Inc. pioneers precision biotech drugs targeting mineral metabolism disorders, blending deep science with patient‑focused therapies—discover the future of metabolic care.

Ardelyx, a biotech leader, targets GI‑tract transporters to correct mineral metabolism and metabolic disorders, driving innovative therapies despite current loss.

Ardelyx faces a major setback after an appeals court upheld Medicare coverage limits, impacting revenue and strategy for its metabolic disorder drugs.

Ardelyx’s innovative drugs target GI transporters to treat mineral metabolism and metabolic disorders, offering new hope for kidney disease patients.

Ardelyx, Inc. innovates in biotech by targeting gastrointestinal transporters to treat mineral metabolism disorders, driving new therapies and improving patient outcomes.

Ardelyx’s IBS‑C study accepted for Digestive Disease Week 2026 poster; shares hit a 200‑day low, while analyst ratings hover around “Moderate Buy.

Ardelyx’s new partnership and promising preclinical data signal a boost for its mineral‑metabolism drugs, while disciplined capital strategy keeps investors focused on long‑term growth.

Ardelyx’s latest SEC filing reveals CMO stock‑unit details amid a dynamic biotech market, spotlighting its focus on innovative metabolic disorder therapies.